Early Use of Dexamethasone versus Sodium Chloride Placebo in Patients with Severe Influenza-Induced Acute Hypoxemic Respiratory Failure (Phase III Randomized Trial)

Registered drug

Early Use of Dexamethasone versus Sodium Chloride Placebo in Patients with Severe Influenza-Induced Acute Hypoxemic Respiratory Failure (Phase III Randomized Trial)

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Centre Hospital Region Metz Thionville

Contact Research Centre

Ischaemic stroke

Not yet recruiting

Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy

Registered drugNo placebo

Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Tenecteplase
Sponsor:Hopital Fondation Adolphe De Rothschild

Contact Research Centre

Central nervous system vasculitis

Not yet recruiting

Rituximab versus azathioprine for remission maintenance in patients with primary angiitis of the central nervous system – randomized controlled trial

Registered drugNo placebo

Rituximab versus azathioprine for remission maintenance in patients with primary angiitis of the central nervous system – randomized controlled trial

Registered drugNo placebo

France

Participants:18–64 years
Substances:Azathioprine
Sponsor:Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

Contact Research Centre

Bacterial sepsis

Not yet recruiting

Individualized beta‑lactam dosing with piperacillin (drug combination) for ICU patients with sepsis caused by gram‑negative bacteria

Registered drugNo placebo

Individualized beta‑lactam dosing with piperacillin (drug combination) for ICU patients with sepsis caused by gram‑negative bacteria

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amoxicillin
Sponsor:Centre Hospitalier Universitaire De Rennes

Contact Research Centre

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Septic coagulopathy

Not yet recruiting

Efficacy of Sivelestat in Patients with Septic Coagulopathy: A Phase IIb Randomized Controlled Trial

Registered drug

Efficacy of Sivelestat in Patients with Septic Coagulopathy: A Phase IIb Randomized Controlled Trial

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Potassium Chloride
Sponsor:Les Hopitaux Universitaires De Strasbourg

Contact Research Centre

T-cell type acute leukaemia

Not yet recruiting

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Asparaginase
Sponsor:Centre Hospitalier De Versailles

Contact Research Centre

Systemic scleroderma

Not yet recruiting

Rituximab versus placebo for maintenance therapy in adults with stabilized systemic sclerosis‑associated interstitial lung disease

Registered drug

Rituximab versus placebo for maintenance therapy in adults with stabilized systemic sclerosis‑associated interstitial lung disease

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Rituximab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Abortion threatened

Not yet recruiting

Comparison of ceftriaxone and azithromycin versus amoxicillin and azithromycin for pregnant women with preterm premature rupture of membranes between 22 and 33 weeks.

Registered drugNo placebo

Comparison of ceftriaxone and azithromycin versus amoxicillin and azithromycin for pregnant women with preterm premature rupture of membranes between 22 and 33 weeks.

Registered drugNo placebo

France

Participants:18–64 years
Substances:Amoxicillin
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Registered drugNo placebo

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Metz

What the registry says about research in the country

01 Oncology & Hematology

Groundbreaking research focusing on multiple myeloma treatments, including novel combinations of therapies and maintenance strategies. Studies evaluating new approaches for lymphoma and advanced breast cancer treatments.

Multiple Myeloma Therapies
Lymphoma Treatments
Breast Cancer Innovations

Several trials exploring targeted therapies and immunotherapy combinations for better patient outcomes.

02 Respiratory Medicine

Advanced research in non-small cell lung cancer treatment, particularly focusing on elderly patients. Studies examining antibiotic optimization in COPD exacerbations.

Lung Cancer Therapeutics
COPD Management
Respiratory Infections

Innovative approaches combining immunotherapy with conventional treatments.

03 Autoimmune Conditions

Clinical investigations in lupus nephritis and atopic dermatitis, exploring steroid-free treatment options and novel biological therapies.

Lupus Treatment Innovations
Dermatological Therapies
Vasculitis Management

Focus on reducing steroid dependency while maintaining treatment efficacy.

Back to France All countries